View Item 

Show simple item record

Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network
dc.contributor.authorHerrera, Alex F.en_US
dc.contributor.authorCrosby‐thompson, Allisonen_US
dc.contributor.authorFriedberg, Jonathan W.en_US
dc.contributor.authorAbel, Gregory A.en_US
dc.contributor.authorCzuczman, Myron S.en_US
dc.contributor.authorGordon, Leo I.en_US
dc.contributor.authorKaminski, Mark S.en_US
dc.contributor.authorMillenson, Michael M.en_US
dc.contributor.authorNademanee, Auayporn P.en_US
dc.contributor.authorNiland, Joyce C.en_US
dc.contributor.authorRodig, Scott J.en_US
dc.contributor.authorRodriguez, Maria A.en_US
dc.contributor.authorZelenetz, Andrew D.en_US
dc.contributor.authorLaCasce, Ann S.en_US
dc.date.accessioned2014-07-03T14:41:29Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-07-03T14:41:29Z
dc.date.issued2014-07-01en_US
dc.identifier.citationHerrera, Alex F.; Crosby‐thompson, Allison ; Friedberg, Jonathan W.; Abel, Gregory A.; Czuczman, Myron S.; Gordon, Leo I.; Kaminski, Mark S.; Millenson, Michael M.; Nademanee, Auayporn P.; Niland, Joyce C.; Rodig, Scott J.; Rodriguez, Maria A.; Zelenetz, Andrew D.; LaCasce, Ann S. (2014). "Comparison of referring and final pathology for patients with Tâ cell lymphoma in the National Comprehensive Cancer Network." Cancer 120(13): 1993-1999.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107537
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherLymphomaen_US
dc.subject.otherT‐Cell Lymphomaen_US
dc.subject.otherDiagnosisen_US
dc.subject.otherOutcomes Researchen_US
dc.subject.otherPathologyen_US
dc.titleComparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Networken_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107537/1/cncr28676.pdf
dc.identifier.doi10.1002/cncr.28676en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceSmith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T‐cell non‐Hodgkin lymphoma. J Clin Oncol. 2013; 31: 3100 ‐ 3109.en_US
dc.identifier.citedreferenceSibon D, Fournier M, Briere J, et al. Long‐term outcome of adults with systemic anaplastic large‐cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol. 2012; 30: 3939 ‐ 3946.en_US
dc.identifier.citedreferenceRodriguez J, Conde E, Gutierrez A, et al. Prolonged survival of patients with angioimmunoblastic T‐cell lymphoma after high‐dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol. 2007; 78: 290 ‐ 296.en_US
dc.identifier.citedreferenceRodriguez J, Conde E, Gutierrez A, et al. Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from the Gel‐Tamo Study Group. Eur J Haematol. 2007; 79: 32 ‐ 38.en_US
dc.identifier.citedreferenceSchetelig J, Fetscher S, Reichle A, et al. Long‐term disease‐free survival in patients with angioimmunoblastic T‐cell lymphoma after high‐dose chemotherapy and autologous stem cell transplantation. Haematologica. 2003; 88: 1272 ‐ 1278.en_US
dc.identifier.citedreferenced'Amore F, Relander T, Lauritzsen GF, et al. Up‐front autologous stem‐cell transplantation in peripheral T‐cell lymphoma: NLG‐T‐01. J Clin Oncol. 2012; 30: 3093 ‐ 3099.en_US
dc.identifier.citedreferenceA clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin's lymphoma. The Non‐Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909 ‐ 3918.en_US
dc.identifier.citedreferenceWeisenburger DD, Anderson JR, Diebold J, et al. Systemic anaplastic large‐cell lymphoma: results from the non‐Hodgkin's lymphoma classification project. Am J Hematol. 2001; 67: 172 ‐ 178.en_US
dc.identifier.citedreferenceRudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T‐cell lymphoma (excluding anaplastic large‐cell lymphoma): results from the Non‐Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002; 13: 140 ‐ 149.en_US
dc.identifier.citedreferenceYounes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN‐35) for relapsed CD30‐positive lymphomas. N Engl J Med. 2010; 363: 1812 ‐ 1821.en_US
dc.identifier.citedreferencePro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190 ‐ 2196.en_US
dc.identifier.citedreferenceO'Connor OA, Pro B, Pinter‐Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T‐cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29: 1182 ‐ 1189.en_US
dc.identifier.citedreferencePiekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T‐cell lymphoma. Blood. 2011; 117: 5827 ‐ 5834.en_US
dc.identifier.citedreferenceCoiffier B, Pro B, Prince HM, et al. Results from a pivotal, open‐label, phase II study of romidepsin in relapsed or refractory peripheral T‐cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30: 631 ‐ 636.en_US
dc.identifier.citedreferenceVose J, Armitage J, Weisenburger D. International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124 ‐ 4130.en_US
dc.identifier.citedreferencePiccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T‐cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013; 31: 3019 ‐ 3025.en_US
dc.identifier.citedreferenceHarris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‐Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835 ‐ 3849.en_US
dc.identifier.citedreferenceLaCasce AS, Kho ME, Friedberg JW, et al. Comparison of referring and final pathology for patients with non‐Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008; 26: 5107 ‐ 5112.en_US
dc.identifier.citedreferenceProctor IE, McNamara C, Rodriguez‐Justo M, Isaacson PG, Ramsay A. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol. 2011; 29: 1431 ‐ 1435.en_US
dc.identifier.citedreferenceFederico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T‐cell lymphoma: analysis of the international peripheral T‐cell lymphoma project. J Clin Oncol. 2013; 31: 240 ‐ 246.en_US
dc.identifier.citedreferenceWeisenburger DD, Savage KJ, Harris NL, et al. Peripheral T‐cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T‐cell Lymphoma Project. Blood. 2011; 117: 3402 ‐ 3408.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28676.pdf
Size:
135.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.